Viking Therapeutics Inc. logo

Viking Therapeutics Inc. (VKTX)

Market Closed
22 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
37. 31
-0.64
-1.6864%
$
4.31B Market Cap
- P/E Ratio
- Div Yield
1.32M Volume
-0.92 Eps
$ 37.95
Previous Close
Add Transaction
Day Range
37.05 38.16
Year Range
22.96 43.15
Want to track VKTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Levi & Korsinsky Reminds Shareholders of an Investigation into Viking Therapeutics, Inc. (VKTX) Regarding Potential Securities Fraud Allegations

Levi & Korsinsky Reminds Shareholders of an Investigation into Viking Therapeutics, Inc. (VKTX) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Accesswire | 1 year ago
3 Things You Need to Know if You Buy Viking Therapeutics Today

3 Things You Need to Know if You Buy Viking Therapeutics Today

3 Things You Need to Know if You Buy Viking Therapeutics Today

Fool | 1 year ago
Is It Too Late to Buy Viking Therapeutics Stock?

Is It Too Late to Buy Viking Therapeutics Stock?

Is It Too Late to Buy Viking Therapeutics Stock?

Fool | 1 year ago
ATTENTION VKTX SHAREHOLDERS: Investors who lost money on Viking Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

ATTENTION VKTX SHAREHOLDERS: Investors who lost money on Viking Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

Fool | 1 year ago
Viking Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viking Therapeutics, Inc. (VKTX)

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
VKTX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Viking Therapeutics, Inc. Shareholders Who Lost Money

VKTX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Viking Therapeutics, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Accesswire | 1 year ago
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?

Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.

Fool | 1 year ago
Lost Money on Viking Therapeutics, Inc. (VKTX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Lost Money on Viking Therapeutics, Inc. (VKTX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 1 year ago
Loading...
Load More